Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR2 | O60603 | 4/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | CASP3 | P42574 | 1/20 | 0.50 |
| ▸ | MDM4 | O15151 | 1/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | MDM2 | Q00987 | 2/20 | 0.48 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13688703 | 1.00 | TLR2 (0.50) | TLR2KMT2ACASP3MDM4TP53 | |
| SCHEMBL1784562 | 1.00 | TLR2 (0.50) | TLR2KMT2ACASP3MDM4TP53 | |
| SCHEMBL15203241 | 0.93 | TLR2 (0.54) | TLR2KMT2ACASP3MDM4TP53 | |
| SCHEMBL10026043 | 0.92 | TLR2 (0.58) | TLR2MDM2 | |
| SCHEMBL29867802 | 0.90 | TLR2 (0.59) | TLR2CASP3MDM4TP53MDM2 | |
| SCHEMBL120255 | 0.90 | TLR2 (0.59) | TLR2CASP3MDM4TP53MDM2 | |
| SCHEMBL7532853 | 0.90 | TLR2 (0.59) | TLR2CASP3MDM4TP53MDM2 | |
| SCHEMBL377523 | 0.90 | MDM4 (0.50) | KMT2ACASP3MDM4TP53MDM2 | |
| SCHEMBL29398908 | 0.90 | TLR2 (0.59) | TLR2CASP3MDM4TP53MDM2 | |
| SCHEMBL30564455 | 0.90 | MDM4 (0.50) | KMT2ACASP3MDM4TP53MDM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102206247-B | Novel peptides as NS3/NS4a serine protease inhibitors of hepatitis C virus | DENDREON CORP | 2013-03-27 | — | — | CN | disclosed |
| US-RE43298-E1 | Peptides as NS3-serine protease inhibitors of hepatitis C virus | SCHERING CORPORATION (US) | 2012-04-03 | — | — | US | disclosed |
| CN-102372764-A | Novel peptides as NS3-serine protease inhibitors of hepatitis c virus | SCHERING CORP | 2012-03-14 | — | — | CN | disclosed |
| CN-102206247-A | Novel peptides as NS3-serine protease inhibitors of hepatitis C virus | DENDREON CORP | 2011-10-05 | — | — | CN | disclosed |
| US-20110117057-A1 | NOVEL PEPTIDES AS NS3-SERINE PROTEASE INHIBITORS OF HEPATITIS C VIRUS | SCHERING CORPORATION (US) | 2011-05-19 | — | — | US | disclosed |
| CN-101792483-A | Novel peptides as inhibitors of hepatitis C virus NS 3-serine protease | SCHERING CORP | 2010-08-04 | — | — | CN | disclosed |
| US-7244721-B2 | Peptides as NS3-serine protease inhibitors of hepatitis C virus | SCHERING CORPORATION (US) | 2007-07-17 | — | — | US | disclosed |
| US-7244721-B2 | Peptides as NS3-serine protease inhibitors of hepatitis C virus | SCHERING CORPORATION (US) | 2007-07-17 | — | — | US | disclosed |
| US-20070032433-A1 | Novel peptides as NS3-serine protease inhibitors of hepatitis C virus | SCHERING CORPORATION CORVAS INTERNATIONAL, LTD. | 2007-02-08 | — | — | US | disclosed |
| US-7169760-B2 | Peptides as NS3-serine protease inhibitors of hepatitis C virus | SCHERING CORPORATION (US) | 2007-01-30 | — | — | US | disclosed |
| CN-1498224-A | Novel peptides as inhibitors of hepatitis C virus NS 3-serine protease | ���鹫˾ | 2004-05-19 | — | — | CN | disclosed |
| CN-1446201-A | Novel peptides as NS3-serine protease inhibitors of hepatitis C virus | SCHERING CORP (US) | 2003-10-01 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110117057-A1 | NOVEL PEPTIDES AS NS3-SERINE PROTEASE INHIBITORS OF HEPATITIS C VIRUS | HPN, TMPRSS15, VIP | TLR2 2661/4885KMT2A 3449/4885CASP3 282/4885 |
| US-20070032433-A1 | Novel peptides as NS3-serine protease inhibitors of hepatitis C virus | HPN, TMPRSS15, VIP | TLR2 2661/4885KMT2A 3449/4885CASP3 282/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.